{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T02:13:58Z","timestamp":1773886438281,"version":"3.50.1"},"reference-count":13,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,3,17]],"date-time":"2015-03-17T00:00:00Z","timestamp":1426550400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Medicine"],"published-print":{"date-parts":[[2015,4]]},"abstract":"<jats:title>SUMMARY<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>Aim of the study was to evaluate performance of a new fully automated platform, <jats:styled-content style=\"fixed-case\">DiaSorin\u2010LIAISON<\/jats:styled-content>\u00ae <jats:styled-content style=\"fixed-case\">XL<\/jats:styled-content> (DiaSorin S.p.A, Vercelli, Italy), in blood donor screening, specifically for hepatitis B surface antigen (<jats:styled-content style=\"fixed-case\">HBsAg<\/jats:styled-content>), hepatitis B core antibodies (anti\u2010<jats:styled-content style=\"fixed-case\">HBc<\/jats:styled-content>), hepatitis C antibodies (anti\u2010<jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>), <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content> p24 antigen, <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content> antibodies, human T\u2010lymphotropic virus types 1 and 2 (<jats:styled-content style=\"fixed-case\">HTLV<\/jats:styled-content>\u20101\/2) and <jats:italic>Treponema pallidum<\/jats:italic> antibodies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Background<\/jats:title><jats:p>In screening for such viral and bacteriological blood\u2010borne infections, sensitivity and specificity are of utmost importance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Sensitivity was evaluated using selected panels of samples previously analysed on the Abbott Architect immunoanalyser (Abbott Laboratories, Abbott Park, IL, USA)\u00a0\u2013\u00a0the gold standard for this evaluation. These samples were confirmed positive for <jats:styled-content style=\"fixed-case\">HBsAg<\/jats:styled-content>, anti\u2010<jats:styled-content style=\"fixed-case\">HBc<\/jats:styled-content>, anti\u2010<jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>, <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content> Ag\/Ab, anti\u2010<jats:styled-content style=\"fixed-case\">HTLV<\/jats:styled-content>\u20101\/2 and antibodies to <jats:italic>T. pallidum<\/jats:italic>, respectively. Specificity analysis was assessed by analysing blood donor samples previously run on the Architect platform and found non\u2010reactive for each marker. A total of 1\u00b7100 donor samples (both new and regular donors) were tested. Previously, non\u2010specific reactive samples were also run for every tested marker, as well as samples with autoimmune antibodies and antibodies to other infections.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Three hundred seventy\u2010eight samples positive for the tested markers (<jats:styled-content style=\"fixed-case\">HBsAg<\/jats:styled-content> <jats:italic>n<\/jats:italic>\u2009=\u200951, anti\u2010<jats:styled-content style=\"fixed-case\">HBc<\/jats:styled-content> <jats:italic>n<\/jats:italic>\u2009=\u200952, anti\u2010<jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> <jats:italic>n<\/jats:italic>\u2009=\u200975, anti\u2010Treponema <jats:italic>n<\/jats:italic>\u2009=\u200955, anti\u2010<jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\u20101 <jats:italic>n<\/jats:italic>\u2009=\u200979, anti\u2010<jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\u20102 <jats:italic>n<\/jats:italic>\u2009=\u200925, anti\u2010<jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content> 1\/2 <jats:italic>n<\/jats:italic>\u2009=\u20093, anti\u2010<jats:styled-content style=\"fixed-case\">HTLV<\/jats:styled-content>\u20101 <jats:italic>n<\/jats:italic>\u2009=\u200928 anti\u2010<jats:styled-content style=\"fixed-case\">HTLV<\/jats:styled-content>\u20102 <jats:italic>n<\/jats:italic>\u2009=\u200910) were tested and found positive, suggesting a high sensitivity. A number of 342\u20131100 negative blood donors (depending on marker) have been tested, with very good specificity for the markers tested, ranging between 99\u00b75 and 100%, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The <jats:styled-content style=\"fixed-case\">LIAISON<\/jats:styled-content>\u00ae <jats:styled-content style=\"fixed-case\">XL<\/jats:styled-content> platform demonstrated very high sensitivity for the markers tested and the specificity necessary to fulfil the stringent requirements for blood donor screening.<\/jats:p><\/jats:sec>","DOI":"10.1111\/tme.12181","type":"journal-article","created":{"date-parts":[[2015,3,17]],"date-time":"2015-03-17T07:12:26Z","timestamp":1426576346000},"page":"101-105","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Performance of Liaison <scp>XL<\/scp> automated immunoassay platform for blood\u2010borne infection screening on hepatitis B, hepatitis C, <scp>HIV<\/scp> 1\/2, <scp>HTLV<\/scp> 1\/2 and <i>Treponema pallidum<\/i> serological markers"],"prefix":"10.1111","volume":"25","author":[{"given":"K.","family":"Malm","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, Faculty of Medicine and Health \u00d6rebro University  \u00d6rebro Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Kragsbjerg","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Faculty of Medicine and Health \u00d6rebro University  \u00d6rebro Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Andersson","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Faculty of Medicine and Health \u00d6rebro University  \u00d6rebro Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,3,17]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.03486-13"},{"key":"e_1_2_7_3_1","first-page":"49","article-title":"Discrepancies between two automated immunoassay systems in determining hepatitis B virus markers in serum samples with concomitant presence of antigens and antibodies","volume":"40","author":"Cheng L.","year":"2010","journal-title":"Annals of Clinical & Laboratory Science"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1990.30991048793.x"},{"key":"e_1_2_7_5_1","unstructured":"European Commission. (2009) 2009\/886\/EC: Commission Decision of 27 November 2009 amending Decision 2002\/364\/EC on common technical specifications for in vitro diagnostic medical devices."},{"key":"e_1_2_7_6_1","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1515\/cclm-2014-0499","article-title":"Operative performances and efficiency for infectious disease testing of two immunochemistry analyzers \u2010 Abbott ARCHITECT i2000SR and DiaSorin Liaison XL","volume":"53","author":"Fruttero E.R.","year":"2015","journal-title":"Clinical Chemistry and Laboratory Medicine"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2013.10.009"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01089-14"},{"key":"e_1_2_7_9_1","first-page":"1606","article-title":"Evaluation of a new screening assay for HTLV\u20101 and \u22122 antibodies for large\u2010scale use","volume":"82","author":"Malm K.","year":"2010","journal-title":"Journal of Clinical Virology"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00316-13"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio.09.69"},{"key":"e_1_2_7_12_1","unstructured":"Socialstyrelsen(2010)Blodverksamhet SOSFS 2009:28. URLhttp:\/\/www.socialstyrelsen.se\/sosfs\/2009\u201028(Accessed 10\/03\/15)."},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2010.01345.x"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/0956462413499909"}],"container-title":["Transfusion Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftme.12181","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tme.12181","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T14:37:57Z","timestamp":1696171077000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tme.12181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,17]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.1111\/tme.12181"],"URL":"https:\/\/doi.org\/10.1111\/tme.12181","archive":["Portico"],"relation":{},"ISSN":["0958-7578","1365-3148"],"issn-type":[{"value":"0958-7578","type":"print"},{"value":"1365-3148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,17]]},"assertion":[{"value":"2014-11-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-02-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-03-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}